#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Cholesterol is predominantly synthesized de novo in the liver with lesser amounts obtained from the diet .
3-1	17-28	Cholesterol	substance	new	coref	5-12
3-2	29-31	is	_	_	_	_
3-3	32-45	predominantly	_	_	_	_
3-4	46-57	synthesized	_	_	_	_
3-5	58-60	de	_	_	_	_
3-6	61-65	novo	_	_	_	_
3-7	66-68	in	_	_	_	_
3-8	69-72	the	object[4]	new[4]	coref	5-26[26_4]
3-9	73-78	liver	object[4]	new[4]	_	_
3-10	79-83	with	object[4]	new[4]	_	_
3-11	84-90	lesser	object[4]|quantity[5]	new[4]|new[5]	_	_
3-12	91-98	amounts	object[4]|quantity[5]	new[4]|new[5]	_	_
3-13	99-107	obtained	_	_	_	_
3-14	108-112	from	_	_	_	_
3-15	113-116	the	abstract[6]	new[6]	_	_
3-16	117-121	diet	abstract[6]	new[6]	_	_
3-17	122-123	.	_	_	_	_

#Text=Dietary intake , de novo synthesis , metabolism and excretion , combine to balance circulating cholesterol levels ensuring extra-hepatic tissues are sufficiently equipped to produce a range of metabolites including steroid hormones , bile acids and seco-steroids .
4-1	124-131	Dietary	substance|event[8]	new|new[8]	_	_
4-2	132-138	intake	event[8]	new[8]	_	_
4-3	139-140	,	_	_	_	_
4-4	141-143	de	abstract[9]	new[9]	_	_
4-5	144-148	novo	abstract[9]	new[9]	_	_
4-6	149-158	synthesis	abstract[9]	new[9]	_	_
4-7	159-160	,	_	_	_	_
4-8	161-171	metabolism	abstract	new	coref	6-10[39_0]
4-9	172-175	and	_	_	_	_
4-10	176-185	excretion	substance	new	_	_
4-11	186-187	,	_	_	_	_
4-12	188-195	combine	_	_	_	_
4-13	196-198	to	_	_	_	_
4-14	199-206	balance	_	_	_	_
4-15	207-218	circulating	abstract[12]	new[12]	_	_
4-16	219-230	cholesterol	abstract[12]	new[12]	_	_
4-17	231-237	levels	abstract[12]	new[12]	_	_
4-18	238-246	ensuring	_	_	_	_
4-19	247-260	extra-hepatic	place[13]	new[13]	coref	8-20[0_13]
4-20	261-268	tissues	place[13]	new[13]	_	_
4-21	269-272	are	_	_	_	_
4-22	273-285	sufficiently	_	_	_	_
4-23	286-294	equipped	_	_	_	_
4-24	295-297	to	_	_	_	_
4-25	298-305	produce	_	_	_	_
4-26	306-307	a	_	_	_	_
4-27	308-313	range	_	_	_	_
4-28	314-316	of	_	_	_	_
4-29	317-328	metabolites	substance[14]	new[14]	_	_
4-30	329-338	including	substance[14]	new[14]	_	_
4-31	339-346	steroid	substance[14]|object|substance[16]	new[14]|new|new[16]	_	_
4-32	347-355	hormones	substance[14]|substance[16]	new[14]|new[16]	_	_
4-33	356-357	,	substance[14]	new[14]	_	_
4-34	358-362	bile	substance[14]|substance[17]	new[14]|new[17]	coref	14-47[118_17]
4-35	363-368	acids	substance[14]|substance[17]	new[14]|new[17]	_	_
4-36	369-372	and	substance[14]	new[14]	_	_
4-37	373-386	seco-steroids	substance[14]|substance	new[14]|new	_	_
4-38	387-388	.	_	_	_	_

#Text=Side-chain hydroxycholesterols ( scOHCs ) are typically formed through hydroxylation of cholesterol by specialized members of the Cytochrome P450 family , which bind and activate the Liver X Receptor-alpha ( LXRA ; gene name NR1H3 ) and beta ( LXRB ; gene name NR1H2 ) transcription factors .
5-1	389-399	Side-chain	substance[19]	new[19]	_	_
5-2	400-419	hydroxycholesterols	substance[19]	new[19]	_	_
5-3	420-421	(	_	_	_	_
5-4	422-428	scOHCs	object	new	coref	8-15[54_0]
5-5	429-430	)	_	_	_	_
5-6	431-434	are	_	_	_	_
5-7	435-444	typically	_	_	_	_
5-8	445-451	formed	_	_	_	_
5-9	452-459	through	_	_	_	_
5-10	460-473	hydroxylation	substance[21]	new[21]	_	_
5-11	474-476	of	substance[21]	new[21]	_	_
5-12	477-488	cholesterol	substance[21]|substance	new[21]|giv	coref	6-8
5-13	489-491	by	_	_	_	_
5-14	492-503	specialized	person[23]	new[23]	_	_
5-15	504-511	members	person[23]	new[23]	_	_
5-16	512-514	of	person[23]	new[23]	_	_
5-17	515-518	the	person[23]|organization[25]	new[23]|new[25]	_	_
5-18	519-529	Cytochrome	person[23]|organization[25]	new[23]|new[25]	_	_
5-19	530-534	P450	person[23]|person|organization[25]	new[23]|new|new[25]	_	_
5-20	535-541	family	person[23]|organization[25]	new[23]|new[25]	_	_
5-21	542-543	,	_	_	_	_
5-22	544-549	which	_	_	_	_
5-23	550-554	bind	_	_	_	_
5-24	555-558	and	_	_	_	_
5-25	559-567	activate	_	_	_	_
5-26	568-571	the	object[26]	giv[26]	coref	7-11[43_26]
5-27	572-577	Liver	object[26]	giv[26]	_	_
5-28	578-579	X	person[27]	new[27]	_	_
5-29	580-594	Receptor-alpha	person[27]	new[27]	_	_
5-30	595-596	(	_	_	_	_
5-31	597-601	LXRA	abstract	new	coref	7-7
5-32	602-603	;	_	_	_	_
5-33	604-608	gene	_	_	_	_
5-34	609-613	name	_	_	_	_
5-35	614-619	NR1H3	abstract	new	_	_
5-36	620-621	)	_	_	_	_
5-37	622-625	and	_	_	_	_
5-38	626-630	beta	abstract	new	_	_
5-39	631-632	(	_	_	_	_
5-40	633-637	LXRB	abstract	new	coref	7-23
5-41	638-639	;	_	_	_	_
5-42	640-644	gene	abstract[32]	new[32]	_	_
5-43	645-649	name	abstract[32]	new[32]	_	_
5-44	650-655	NR1H2	_	_	_	_
5-45	656-657	)	_	_	_	_
5-46	658-671	transcription	abstract[33]	new[33]	_	_
5-47	672-679	factors	abstract[33]	new[33]	_	_
5-48	680-681	.	_	_	_	_

#Text=LXR target genes are typically involved in cholesterol and fatty acid metabolism .
6-1	682-685	LXR	abstract|abstract[36]	new|new[36]	coref|coref	10-22|10-22
6-2	686-692	target	abstract|abstract[36]	new|new[36]	_	_
6-3	693-698	genes	abstract[36]	new[36]	_	_
6-4	699-702	are	_	_	_	_
6-5	703-712	typically	_	_	_	_
6-6	713-721	involved	_	_	_	_
6-7	722-724	in	_	_	_	_
6-8	725-736	cholesterol	substance	giv	coref	23-41
6-9	737-740	and	_	_	_	_
6-10	741-746	fatty	abstract[39]	giv[39]	coref	23-41[219_39]
6-11	747-751	acid	substance|abstract[39]	new|giv[39]	_	_
6-12	752-762	metabolism	abstract[39]	giv[39]	_	_
6-13	763-764	.	_	_	_	_

#Text=In normal tissue , expression of LXRA is inducible in the liver , intestine , macrophages and adipocytes , whilst expression of LXRB is more ubiquitous .
7-1	765-767	In	_	_	_	_
7-2	768-774	normal	object[40]	new[40]	coref	20-13[173_40]
7-3	775-781	tissue	object[40]	new[40]	_	_
7-4	782-783	,	_	_	_	_
7-5	784-794	expression	abstract[41]	new[41]	_	_
7-6	795-797	of	abstract[41]	new[41]	_	_
7-7	798-802	LXRA	abstract[41]|abstract	new[41]|giv	coref	8-8
7-8	803-805	is	_	_	_	_
7-9	806-815	inducible	_	_	_	_
7-10	816-818	in	_	_	_	_
7-11	819-822	the	object[43]	giv[43]	_	_
7-12	823-828	liver	object[43]	giv[43]	_	_
7-13	829-830	,	_	_	_	_
7-14	831-840	intestine	place	new	_	_
7-15	841-842	,	_	_	_	_
7-16	843-854	macrophages	object	new	_	_
7-17	855-858	and	_	_	_	_
7-18	859-869	adipocytes	object	new	_	_
7-19	870-871	,	_	_	_	_
7-20	872-878	whilst	_	_	_	_
7-21	879-889	expression	abstract[47]	new[47]	_	_
7-22	890-892	of	abstract[47]	new[47]	_	_
7-23	893-897	LXRB	abstract[47]|abstract	new[47]|giv	coref	8-10
7-24	898-900	is	_	_	_	_
7-25	901-905	more	_	_	_	_
7-26	906-916	ubiquitous	_	_	_	_
7-27	917-918	.	_	_	_	_

#Text=As well as differences in expression of LXRA and LXRB , local concentrations of the scOHCs differ considerably between tissues , and relative to each other , sometimes by as much as 1000-fold and variance can also depend on disease status .
8-1	919-921	As	_	_	_	_
8-2	922-926	well	_	_	_	_
8-3	927-929	as	_	_	_	_
8-4	930-941	differences	abstract[49]	new[49]	_	_
8-5	942-944	in	abstract[49]	new[49]	_	_
8-6	945-955	expression	abstract[49]|abstract[50]	new[49]|new[50]	_	_
8-7	956-958	of	abstract[49]|abstract[50]	new[49]|new[50]	_	_
8-8	959-963	LXRA	abstract[49]|abstract[50]|abstract	new[49]|new[50]|giv	coref	14-1
8-9	964-967	and	abstract[49]|abstract[50]	new[49]|new[50]	_	_
8-10	968-972	LXRB	abstract[49]|abstract[50]|abstract	new[49]|new[50]|giv	coref	14-9[99_0]
8-11	973-974	,	_	_	_	_
8-12	975-980	local	animal[53]	new[53]	coref	11-8[71_53]
8-13	981-995	concentrations	animal[53]	new[53]	_	_
8-14	996-998	of	animal[53]	new[53]	_	_
8-15	999-1002	the	animal[53]|object[54]	new[53]|giv[54]	coref	9-3[58_54]
8-16	1003-1009	scOHCs	animal[53]|object[54]	new[53]|giv[54]	_	_
8-17	1010-1016	differ	_	_	_	_
8-18	1017-1029	considerably	_	_	_	_
8-19	1030-1037	between	_	_	_	_
8-20	1038-1045	tissues	place	giv	_	_
8-21	1046-1047	,	_	_	_	_
8-22	1048-1051	and	_	_	_	_
8-23	1052-1060	relative	_	_	_	_
8-24	1061-1063	to	_	_	_	_
8-25	1064-1068	each	_	_	_	_
8-26	1069-1074	other	_	_	_	_
8-27	1075-1076	,	_	_	_	_
8-28	1077-1086	sometimes	_	_	_	_
8-29	1087-1089	by	_	_	_	_
8-30	1090-1092	as	_	_	_	_
8-31	1093-1097	much	_	_	_	_
8-32	1098-1100	as	_	_	_	_
8-33	1101-1110	1000-fold	_	_	_	_
8-34	1111-1114	and	_	_	_	_
8-35	1115-1123	variance	_	_	_	_
8-36	1124-1127	can	_	_	_	_
8-37	1128-1132	also	_	_	_	_
8-38	1133-1139	depend	_	_	_	_
8-39	1140-1142	on	_	_	_	_
8-40	1143-1150	disease	abstract|abstract[57]	new|new[57]	coref|coref|coref|coref	20-33[179_0]|23-11[210_57]|20-33[179_0]|23-11[210_57]
8-41	1151-1157	status	abstract[57]	new[57]	_	_
8-42	1158-1159	.	_	_	_	_

#Text=Furthermore , the different scOHCs have varying capacities to activate LXR-mediated transcription , imposing an element of selective modulation onto signalling .
9-1	1160-1171	Furthermore	_	_	_	_
9-2	1172-1173	,	_	_	_	_
9-3	1174-1177	the	object[58]	giv[58]	coref	20-5[171_58]
9-4	1178-1187	different	object[58]	giv[58]	_	_
9-5	1188-1194	scOHCs	object[58]	giv[58]	_	_
9-6	1195-1199	have	_	_	_	_
9-7	1200-1207	varying	abstract[59]	new[59]	_	_
9-8	1208-1218	capacities	abstract[59]	new[59]	_	_
9-9	1219-1221	to	_	_	_	_
9-10	1222-1230	activate	_	_	_	_
9-11	1231-1243	LXR-mediated	abstract[60]	new[60]	_	_
9-12	1244-1257	transcription	abstract[60]	new[60]	_	_
9-13	1258-1259	,	_	_	_	_
9-14	1260-1268	imposing	_	_	_	_
9-15	1269-1271	an	abstract[61]	new[61]	coref	12-35[86_61]
9-16	1272-1279	element	abstract[61]	new[61]	_	_
9-17	1280-1282	of	abstract[61]	new[61]	_	_
9-18	1283-1292	selective	abstract[61]|abstract[62]	new[61]|new[62]	_	_
9-19	1293-1303	modulation	abstract[61]|abstract[62]	new[61]|new[62]	_	_
9-20	1304-1308	onto	abstract[61]|abstract[62]	new[61]|new[62]	_	_
9-21	1309-1319	signalling	abstract[61]|abstract[62]|abstract	new[61]|new[62]|new	coref	15-12[130_0]
9-22	1320-1321	.	_	_	_	_

#Text=26-OHC ( commonly referred to as 27-OHC ) for example is the most abundant scOHC , but is a relatively weak LXR agonist .
10-1	1322-1328	26-OHC	abstract	new	coref	10-12[66_0]
10-2	1329-1330	(	_	_	_	_
10-3	1331-1339	commonly	_	_	_	_
10-4	1340-1348	referred	_	_	_	_
10-5	1349-1351	to	_	_	_	_
10-6	1352-1354	as	_	_	_	_
10-7	1355-1361	27-OHC	abstract	new	_	_
10-8	1362-1363	)	_	_	_	_
10-9	1364-1367	for	_	_	_	_
10-10	1368-1375	example	_	_	_	_
10-11	1376-1378	is	_	_	_	_
10-12	1379-1382	the	abstract[66]	giv[66]	coref	11-8[0_66]
10-13	1383-1387	most	abstract[66]	giv[66]	_	_
10-14	1388-1396	abundant	abstract[66]	giv[66]	_	_
10-15	1397-1402	scOHC	abstract[66]	giv[66]	_	_
10-16	1403-1404	,	abstract[66]	giv[66]	_	_
10-17	1405-1408	but	abstract[66]	giv[66]	_	_
10-18	1409-1411	is	abstract[66]	giv[66]	_	_
10-19	1412-1413	a	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
10-20	1414-1424	relatively	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
10-21	1425-1429	weak	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
10-22	1430-1433	LXR	abstract[66]|abstract|abstract[68]	giv[66]|giv|new[68]	coref	15-12
10-23	1434-1441	agonist	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
10-24	1442-1443	.	_	_	_	_

#Text=Moreover , there is little difference in scOHC concentrations between breast cancer subtypes .
11-1	1444-1452	Moreover	_	_	_	_
11-2	1453-1454	,	_	_	_	_
11-3	1455-1460	there	_	_	_	_
11-4	1461-1463	is	_	_	_	_
11-5	1464-1470	little	abstract[69]	new[69]	coref	21-23[189_69]
11-6	1471-1481	difference	abstract[69]	new[69]	_	_
11-7	1482-1484	in	abstract[69]	new[69]	_	_
11-8	1485-1490	scOHC	abstract[69]|abstract|animal[71]	new[69]|giv|giv[71]	coref|coref|coref|coref	15-3|15-3[126_71]|15-3|15-3[126_71]
11-9	1491-1505	concentrations	abstract[69]|animal[71]	new[69]|giv[71]	_	_
11-10	1506-1513	between	abstract[69]|animal[71]	new[69]|giv[71]	_	_
11-11	1514-1520	breast	abstract[69]|animal[71]|place|abstract[74]	new[69]|giv[71]|new|new[74]	coref|coref	21-29[193_74]|21-29[193_74]
11-12	1521-1527	cancer	abstract[69]|animal[71]|abstract|abstract[74]	new[69]|giv[71]|new|new[74]	coref	14-25
11-13	1528-1536	subtypes	abstract[69]|animal[71]|abstract[74]	new[69]|giv[71]|new[74]	_	_
11-14	1537-1538	.	_	_	_	_

#Text=Transcriptional activity of the LXRs , like the other members of the Nuclear Receptor ( NR ) superfamily , is not just regulated by ligand bioavailability ; chromatin environment , cross-talk and competition for response element binding with other NRs , as well as cell- and tissue-type dependent expression of cofactors are also key mediators .
12-1	1539-1554	Transcriptional	abstract[75]	new[75]	_	_
12-2	1555-1563	activity	abstract[75]	new[75]	_	_
12-3	1564-1566	of	abstract[75]	new[75]	_	_
12-4	1567-1570	the	abstract[75]|object[76]	new[75]|new[76]	_	_
12-5	1571-1575	LXRs	abstract[75]|object[76]	new[75]|new[76]	_	_
12-6	1576-1577	,	abstract[75]	new[75]	_	_
12-7	1578-1582	like	abstract[75]	new[75]	_	_
12-8	1583-1586	the	abstract[75]|person[77]	new[75]|new[77]	_	_
12-9	1587-1592	other	abstract[75]|person[77]	new[75]|new[77]	_	_
12-10	1593-1600	members	abstract[75]|person[77]	new[75]|new[77]	_	_
12-11	1601-1603	of	abstract[75]|person[77]	new[75]|new[77]	_	_
12-12	1604-1607	the	abstract[75]|person[77]|substance[78]	new[75]|new[77]|new[78]	appos	12-16[0_78]
12-13	1608-1615	Nuclear	abstract[75]|person[77]|substance[78]	new[75]|new[77]|new[78]	_	_
12-14	1616-1624	Receptor	abstract[75]|person[77]|substance[78]	new[75]|new[77]|new[78]	_	_
12-15	1625-1626	(	_	_	_	_
12-16	1627-1629	NR	substance	giv	coref	14-40[116_0]
12-17	1630-1631	)	_	_	_	_
12-18	1632-1643	superfamily	person	new	_	_
12-19	1644-1645	,	_	_	_	_
12-20	1646-1648	is	_	_	_	_
12-21	1649-1652	not	_	_	_	_
12-22	1653-1657	just	_	_	_	_
12-23	1658-1667	regulated	_	_	_	_
12-24	1668-1670	by	_	_	_	_
12-25	1671-1677	ligand	organization|event[82]	new|new[82]	appos|coref|appos|coref	12-28[84_82]|14-65|12-28[84_82]|14-65
12-26	1678-1693	bioavailability	event[82]	new[82]	_	_
12-27	1694-1695	;	_	_	_	_
12-28	1696-1705	chromatin	substance|abstract[84]	new|giv[84]	coref|coref	22-4[197_84]|22-4[197_84]
12-29	1706-1717	environment	abstract[84]	giv[84]	_	_
12-30	1718-1719	,	abstract[84]	giv[84]	_	_
12-31	1720-1730	cross-talk	abstract[84]	giv[84]	_	_
12-32	1731-1734	and	abstract[84]	giv[84]	_	_
12-33	1735-1746	competition	abstract[84]	giv[84]	_	_
12-34	1747-1750	for	abstract[84]	giv[84]	_	_
12-35	1751-1759	response	abstract[84]|abstract|abstract[86]	giv[84]|new|giv[86]	_	_
12-36	1760-1767	element	abstract[84]|abstract[86]	giv[84]|giv[86]	_	_
12-37	1768-1775	binding	_	_	_	_
12-38	1776-1780	with	_	_	_	_
12-39	1781-1786	other	abstract[87]	new[87]	_	_
12-40	1787-1790	NRs	abstract[87]	new[87]	_	_
12-41	1791-1792	,	_	_	_	_
12-42	1793-1795	as	_	_	_	_
12-43	1796-1800	well	_	_	_	_
12-44	1801-1803	as	_	_	_	_
12-45	1804-1809	cell-	abstract[88]	new[88]	_	_
12-46	1810-1813	and	abstract[88]	new[88]	_	_
12-47	1814-1825	tissue-type	abstract[88]	new[88]	_	_
12-48	1826-1835	dependent	abstract[88]	new[88]	_	_
12-49	1836-1846	expression	abstract[88]	new[88]	_	_
12-50	1847-1849	of	abstract[88]	new[88]	_	_
12-51	1850-1859	cofactors	abstract[88]|substance	new[88]|new	_	_
12-52	1860-1863	are	_	_	_	_
12-53	1864-1868	also	_	_	_	_
12-54	1869-1872	key	abstract[90]	new[90]	_	_
12-55	1873-1882	mediators	abstract[90]	new[90]	_	_
12-56	1883-1884	.	_	_	_	_

#Text=For example , the expression of corepressors such as NCOR1 and NCOR2/SMRT determine how several cancers respond to nutritive ligands .
13-1	1885-1888	For	_	_	_	_
13-2	1889-1896	example	_	_	_	_
13-3	1897-1898	,	_	_	_	_
13-4	1899-1902	the	abstract[91]	new[91]	coref	22-14[203_91]
13-5	1903-1913	expression	abstract[91]	new[91]	_	_
13-6	1914-1916	of	abstract[91]	new[91]	_	_
13-7	1917-1929	corepressors	abstract[91]|abstract[92]	new[91]|new[92]	coref	14-11[100_92]
13-8	1930-1934	such	abstract[91]|abstract[92]	new[91]|new[92]	_	_
13-9	1935-1937	as	abstract[91]|abstract[92]	new[91]|new[92]	_	_
13-10	1938-1943	NCOR1	abstract[91]|abstract[92]|abstract	new[91]|new[92]|new	coref	14-13
13-11	1944-1947	and	abstract[91]|abstract[92]	new[91]|new[92]	_	_
13-12	1948-1958	NCOR2/SMRT	abstract[91]|abstract[92]|organization	new[91]|new[92]|new	_	_
13-13	1959-1968	determine	_	_	_	_
13-14	1969-1972	how	_	_	_	_
13-15	1973-1980	several	abstract[95]	new[95]	_	_
13-16	1981-1988	cancers	abstract[95]	new[95]	_	_
13-17	1989-1996	respond	_	_	_	_
13-18	1997-1999	to	_	_	_	_
13-19	2000-2009	nutritive	substance[96]	new[96]	_	_
13-20	2010-2017	ligands	substance[96]	new[96]	_	_
13-21	2018-2019	.	_	_	_	_

#Text=LXRA has a 100-fold higher binding affinity than LXRB for the corepressors NCOR1 and NCOR2 and deregulation of these corepressors allows prostate and bladder cancer cells to evade cancer suppressive signals of Vitamin D ( through repression of Vitamin D Receptor ( VDR ) ) and omega-3 fatty acids ( through repression of peroxisome proliferator-activated receptors ( PPARs ) ) by impairing sensitivity to ligand .
14-1	2020-2024	LXRA	place	giv	_	_
14-2	2025-2028	has	_	_	_	_
14-3	2029-2030	a	abstract[98]	new[98]	_	_
14-4	2031-2039	100-fold	abstract[98]	new[98]	_	_
14-5	2040-2046	higher	abstract[98]	new[98]	_	_
14-6	2047-2054	binding	abstract[98]	new[98]	_	_
14-7	2055-2063	affinity	abstract[98]	new[98]	_	_
14-8	2064-2068	than	abstract[98]	new[98]	_	_
14-9	2069-2073	LXRB	abstract[98]|abstract[99]	new[98]|giv[99]	_	_
14-10	2074-2077	for	abstract[98]|abstract[99]	new[98]|giv[99]	_	_
14-11	2078-2081	the	abstract[98]|abstract[99]|abstract[100]	new[98]|giv[99]|giv[100]	coref	14-19[104_100]
14-12	2082-2094	corepressors	abstract[98]|abstract[99]|abstract[100]	new[98]|giv[99]|giv[100]	_	_
14-13	2095-2100	NCOR1	abstract	giv	_	_
14-14	2101-2104	and	_	_	_	_
14-15	2105-2110	NCOR2	organization	new	_	_
14-16	2111-2114	and	_	_	_	_
14-17	2115-2127	deregulation	event[103]	new[103]	_	_
14-18	2128-2130	of	event[103]	new[103]	_	_
14-19	2131-2136	these	event[103]|abstract[104]	new[103]|giv[104]	_	_
14-20	2137-2149	corepressors	event[103]|abstract[104]	new[103]|giv[104]	_	_
14-21	2150-2156	allows	_	_	_	_
14-22	2157-2165	prostate	place	new	_	_
14-23	2166-2169	and	_	_	_	_
14-24	2170-2177	bladder	object|object[108]	new|new[108]	coref|coref	19-19[169_108]|19-19[169_108]
14-25	2178-2184	cancer	abstract|object[108]	giv|new[108]	coref	14-29
14-26	2185-2190	cells	object[108]	new[108]	_	_
14-27	2191-2193	to	_	_	_	_
14-28	2194-2199	evade	_	_	_	_
14-29	2200-2206	cancer	abstract	giv	coref	16-2
14-30	2207-2218	suppressive	abstract[110]	new[110]	_	_
14-31	2219-2226	signals	abstract[110]	new[110]	_	_
14-32	2227-2229	of	abstract[110]	new[110]	_	_
14-33	2230-2237	Vitamin	abstract[110]|substance|person[112]	new[110]|new|new[112]	coref|coref|coref|coref	14-39|14-40[0_112]|14-39|14-40[0_112]
14-34	2238-2239	D	abstract[110]|person[112]	new[110]|new[112]	_	_
14-35	2240-2241	(	abstract[110]	new[110]	_	_
14-36	2242-2249	through	abstract[110]	new[110]	_	_
14-37	2250-2260	repression	abstract[110]|event[113]	new[110]|new[113]	_	_
14-38	2261-2263	of	abstract[110]|event[113]	new[110]|new[113]	_	_
14-39	2264-2271	Vitamin	abstract[110]|event[113]|substance	new[110]|new[113]|giv	_	_
14-40	2272-2273	D	abstract[110]|event[113]|person|substance[116]	new[110]|new[113]|giv|giv[116]	coref|coref	18-2[155_116]|18-2[155_116]
14-41	2274-2282	Receptor	abstract[110]|event[113]|substance[116]	new[110]|new[113]|giv[116]	_	_
14-42	2283-2284	(	abstract[110]	new[110]	_	_
14-43	2285-2288	VDR	abstract[110]|place	new[110]|new	_	_
14-44	2289-2290	)	abstract[110]	new[110]	_	_
14-45	2291-2292	)	abstract[110]	new[110]	_	_
14-46	2293-2296	and	abstract[110]	new[110]	_	_
14-47	2297-2304	omega-3	abstract[110]|substance[118]	new[110]|giv[118]	_	_
14-48	2305-2310	fatty	abstract[110]|substance[118]	new[110]|giv[118]	_	_
14-49	2311-2316	acids	abstract[110]|substance[118]	new[110]|giv[118]	_	_
14-50	2317-2318	(	abstract[110]|substance[118]	new[110]|giv[118]	_	_
14-51	2319-2326	through	abstract[110]|substance[118]	new[110]|giv[118]	_	_
14-52	2327-2337	repression	abstract[110]|substance[118]|event[119]	new[110]|giv[118]|new[119]	_	_
14-53	2338-2340	of	abstract[110]|substance[118]|event[119]	new[110]|giv[118]|new[119]	_	_
14-54	2341-2351	peroxisome	abstract[110]|substance[118]|event[119]|abstract|abstract[121]	new[110]|giv[118]|new[119]|new|new[121]	appos|appos	14-58[0_121]|14-58[0_121]
14-55	2352-2374	proliferator-activated	abstract[110]|substance[118]|event[119]|abstract[121]	new[110]|giv[118]|new[119]|new[121]	_	_
14-56	2375-2384	receptors	abstract[110]|substance[118]|event[119]|abstract[121]	new[110]|giv[118]|new[119]|new[121]	_	_
14-57	2385-2386	(	_	_	_	_
14-58	2387-2392	PPARs	abstract	giv	_	_
14-59	2393-2394	)	_	_	_	_
14-60	2395-2396	)	_	_	_	_
14-61	2397-2399	by	_	_	_	_
14-62	2400-2409	impairing	_	_	_	_
14-63	2410-2421	sensitivity	abstract[123]	new[123]	_	_
14-64	2422-2424	to	abstract[123]	new[123]	_	_
14-65	2425-2431	ligand	abstract[123]|organization	new[123]|giv	coref	21-5
14-66	2432-2433	.	_	_	_	_

#Text=Simply measuring scOHC concentrations does not sufficiently determine their contributions to LXR signalling ; concentration and activation potential should be assessed in combination .
15-1	2434-2440	Simply	_	_	_	_
15-2	2441-2450	measuring	_	_	_	_
15-3	2451-2456	scOHC	substance|animal[126]	giv|giv[126]	ana|coref|ana|coref	15-9[0_126]|18-12|15-9[0_126]|18-12
15-4	2457-2471	concentrations	animal[126]	giv[126]	_	_
15-5	2472-2476	does	_	_	_	_
15-6	2477-2480	not	_	_	_	_
15-7	2481-2493	sufficiently	_	_	_	_
15-8	2494-2503	determine	_	_	_	_
15-9	2504-2509	their	animal|abstract[128]	giv|new[128]	_	_
15-10	2510-2523	contributions	abstract[128]	new[128]	_	_
15-11	2524-2526	to	abstract[128]	new[128]	_	_
15-12	2527-2530	LXR	abstract[128]|abstract|abstract[130]	new[128]|giv|giv[130]	coref|coref|coref|coref	16-9[0_130]|21-4|16-9[0_130]|21-4
15-13	2531-2541	signalling	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
15-14	2542-2543	;	_	_	_	_
15-15	2544-2557	concentration	substance	new	_	_
15-16	2558-2561	and	_	_	_	_
15-17	2562-2572	activation	abstract|abstract[133]	new|new[133]	coref|coref|coref|coref	22-7|22-7[199_133]|22-7|22-7[199_133]
15-18	2573-2582	potential	abstract[133]	new[133]	_	_
15-19	2583-2589	should	_	_	_	_
15-20	2590-2592	be	_	_	_	_
15-21	2593-2601	assessed	_	_	_	_
15-22	2602-2604	in	_	_	_	_
15-23	2605-2616	combination	abstract	new	_	_
15-24	2617-2618	.	_	_	_	_

#Text=In cancer , the function of the scOHC-LXR signalling axis appears site specific as both tumour suppressive and promoting roles have been described .
16-1	2619-2621	In	_	_	_	_
16-2	2622-2628	cancer	abstract	giv	coref	17-16[149_0]
16-3	2629-2630	,	_	_	_	_
16-4	2631-2634	the	abstract[136]	new[136]	_	_
16-5	2635-2643	function	abstract[136]	new[136]	_	_
16-6	2644-2646	of	abstract[136]	new[136]	_	_
16-7	2647-2650	the	abstract[136]|abstract[139]	new[136]|new[139]	_	_
16-8	2651-2660	scOHC-LXR	abstract[136]|object|abstract[139]	new[136]|new|new[139]	coref	17-4
16-9	2661-2671	signalling	abstract[136]|abstract|abstract[139]	new[136]|giv|new[139]	coref	17-4[144_0]
16-10	2672-2676	axis	abstract[136]|abstract[139]	new[136]|new[139]	_	_
16-11	2677-2684	appears	_	_	_	_
16-12	2685-2689	site	abstract[140]	new[140]	_	_
16-13	2690-2698	specific	abstract[140]	new[140]	_	_
16-14	2699-2701	as	_	_	_	_
16-15	2702-2706	both	abstract[141]|abstract[142]	new[141]|new[142]	coref|coref|coref|coref	21-29[0_141]|23-37[217_142]|21-29[0_141]|23-37[217_142]
16-16	2707-2713	tumour	abstract[141]|abstract[142]	new[141]|new[142]	_	_
16-17	2714-2725	suppressive	abstract[142]	new[142]	_	_
16-18	2726-2729	and	abstract[142]	new[142]	_	_
16-19	2730-2739	promoting	abstract[142]	new[142]	_	_
16-20	2740-2745	roles	abstract[142]	new[142]	_	_
16-21	2746-2750	have	_	_	_	_
16-22	2751-2755	been	_	_	_	_
16-23	2756-2765	described	_	_	_	_
16-24	2766-2767	.	_	_	_	_

#Text=For example , scOHC-LXR signalling impairs invasion and angiogenesis in melanoma and is anti-proliferative in lung cancer in vivo , as it is in almost every cancer cell line studied in vitro .
17-1	2768-2771	For	_	_	_	_
17-2	2772-2779	example	_	_	_	_
17-3	2780-2781	,	_	_	_	_
17-4	2782-2791	scOHC-LXR	abstract|abstract[144]	giv|giv[144]	coref|coref|coref|coref	23-29|23-29[215_144]|23-29|23-29[215_144]
17-5	2792-2802	signalling	abstract[144]	giv[144]	_	_
17-6	2803-2810	impairs	_	_	_	_
17-7	2811-2819	invasion	event	new	_	_
17-8	2820-2823	and	_	_	_	_
17-9	2824-2836	angiogenesis	abstract	new	_	_
17-10	2837-2839	in	_	_	_	_
17-11	2840-2848	melanoma	abstract	new	_	_
17-12	2849-2852	and	_	_	_	_
17-13	2853-2855	is	_	_	_	_
17-14	2856-2874	anti-proliferative	_	_	_	_
17-15	2875-2877	in	_	_	_	_
17-16	2878-2882	lung	object|abstract[149]	new|giv[149]	ana|ana	17-22[0_149]|17-22[0_149]
17-17	2883-2889	cancer	abstract[149]	giv[149]	_	_
17-18	2890-2892	in	abstract[149]	giv[149]	_	_
17-19	2893-2897	vivo	abstract[149]	giv[149]	_	_
17-20	2898-2899	,	_	_	_	_
17-21	2900-2902	as	_	_	_	_
17-22	2903-2905	it	abstract	giv	coref	17-27
17-23	2906-2908	is	_	_	_	_
17-24	2909-2911	in	_	_	_	_
17-25	2912-2918	almost	object[153]	new[153]	_	_
17-26	2919-2924	every	object[153]	new[153]	_	_
17-27	2925-2931	cancer	abstract|object[153]	giv|new[153]	coref	18-6[157_0]
17-28	2932-2936	cell	object|object[153]	new|new[153]	_	_
17-29	2937-2941	line	object[153]	new[153]	_	_
17-30	2942-2949	studied	_	_	_	_
17-31	2950-2952	in	_	_	_	_
17-32	2953-2958	vitro	_	_	_	_
17-33	2959-2960	.	_	_	_	_

#Text=In Oestrogen Receptor ( ER)-positive Breast Cancer ( BCa ) however 26-OHC promotes growth in vivo via ER-alpha .
18-1	2961-2963	In	_	_	_	_
18-2	2964-2973	Oestrogen	substance|substance[155]	new|giv[155]	coref|coref	23-12[0_155]|23-12[0_155]
18-3	2974-2982	Receptor	substance[155]	giv[155]	_	_
18-4	2983-2984	(	_	_	_	_
18-5	2985-2997	ER)-positive	person	new	_	_
18-6	2998-3004	Breast	abstract[157]	giv[157]	coref	23-44[0_157]
18-7	3005-3011	Cancer	abstract[157]	giv[157]	_	_
18-8	3012-3013	(	_	_	_	_
18-9	3014-3017	BCa	object	new	coref	19-3
18-10	3018-3019	)	_	_	_	_
18-11	3020-3027	however	_	_	_	_
18-12	3028-3034	26-OHC	substance	giv	coref	19-3[164_0]
18-13	3035-3043	promotes	_	_	_	_
18-14	3044-3050	growth	abstract[160]	new[160]	_	_
18-15	3051-3053	in	abstract[160]	new[160]	_	_
18-16	3054-3058	vivo	abstract[160]	new[160]	_	_
18-17	3059-3062	via	abstract[160]	new[160]	_	_
18-18	3063-3071	ER-alpha	abstract[160]|substance	new[160]|new	_	_
18-19	3072-3073	.	_	_	_	_

#Text=In ER-negative BCa 26-OHC drives the epithelial-to-mesenchymal transition and promotes colonization of metastatic sites in through mobilization of γδ-T cells .
19-1	3074-3076	In	_	_	_	_
19-2	3077-3088	ER-negative	person	new	ana	20-31[178_0]
19-3	3089-3092	BCa	object|substance[164]	giv|giv[164]	coref|coref|coref|coref	20-10[172_0]|22-4[0_164]|20-10[172_0]|22-4[0_164]
19-4	3093-3099	26-OHC	substance[164]	giv[164]	_	_
19-5	3100-3106	drives	_	_	_	_
19-6	3107-3110	the	event[165]	new[165]	_	_
19-7	3111-3136	epithelial-to-mesenchymal	event[165]	new[165]	_	_
19-8	3137-3147	transition	event[165]	new[165]	_	_
19-9	3148-3151	and	_	_	_	_
19-10	3152-3160	promotes	_	_	_	_
19-11	3161-3173	colonization	event[166]	new[166]	_	_
19-12	3174-3176	of	event[166]	new[166]	_	_
19-13	3177-3187	metastatic	event[166]|place[167]	new[166]|new[167]	_	_
19-14	3188-3193	sites	event[166]|place[167]	new[166]|new[167]	_	_
19-15	3194-3196	in	_	_	_	_
19-16	3197-3204	through	_	_	_	_
19-17	3205-3217	mobilization	event[168]	new[168]	_	_
19-18	3218-3220	of	event[168]	new[168]	_	_
19-19	3221-3225	γδ-T	event[168]|object[169]	new[168]|giv[169]	_	_
19-20	3226-3231	cells	event[168]|object[169]	new[168]|giv[169]	_	_
19-21	3232-3233	.	_	_	_	_

#Text=Furthermore , concentrations of several scOHCs are altered in BCa relative to normal tissue , and 25-OHC is elevated in the circulation of BCa patients who have relapsed compared to those with primary disease .
20-1	3234-3245	Furthermore	_	_	_	_
20-2	3246-3247	,	_	_	_	_
20-3	3248-3262	concentrations	animal[170]	new[170]	coref	21-26[191_170]
20-4	3263-3265	of	animal[170]	new[170]	_	_
20-5	3266-3273	several	animal[170]|object[171]	new[170]|giv[171]	_	_
20-6	3274-3280	scOHCs	animal[170]|object[171]	new[170]|giv[171]	_	_
20-7	3281-3284	are	_	_	_	_
20-8	3285-3292	altered	_	_	_	_
20-9	3293-3295	in	_	_	_	_
20-10	3296-3299	BCa	object[172]	giv[172]	coref	20-24[0_172]
20-11	3300-3308	relative	object[172]	giv[172]	_	_
20-12	3309-3311	to	_	_	_	_
20-13	3312-3318	normal	object[173]	giv[173]	_	_
20-14	3319-3325	tissue	object[173]	giv[173]	_	_
20-15	3326-3327	,	_	_	_	_
20-16	3328-3331	and	_	_	_	_
20-17	3332-3338	25-OHC	quantity	new	_	_
20-18	3339-3341	is	_	_	_	_
20-19	3342-3350	elevated	_	_	_	_
20-20	3351-3353	in	_	_	_	_
20-21	3354-3357	the	abstract[175]	new[175]	_	_
20-22	3358-3369	circulation	abstract[175]	new[175]	_	_
20-23	3370-3372	of	abstract[175]	new[175]	_	_
20-24	3373-3376	BCa	abstract[175]|abstract|person[177]	new[175]|giv|new[177]	coref|coref|coref|coref	21-10|23-49[0_177]|21-10|23-49[0_177]
20-25	3377-3385	patients	abstract[175]|person[177]	new[175]|new[177]	_	_
20-26	3386-3389	who	_	_	_	_
20-27	3390-3394	have	_	_	_	_
20-28	3395-3403	relapsed	_	_	_	_
20-29	3404-3412	compared	_	_	_	_
20-30	3413-3415	to	_	_	_	_
20-31	3416-3421	those	person[178]	giv[178]	_	_
20-32	3422-3426	with	person[178]	giv[178]	_	_
20-33	3427-3434	primary	person[178]|abstract[179]	giv[178]|giv[179]	_	_
20-34	3435-3442	disease	person[178]|abstract[179]	giv[178]|giv[179]	_	_
20-35	3443-3444	.	_	_	_	_

#Text=We recently evaluated LXR ligand bio-availability in a small BCa cohort and found large inter tumoural heterogeneity in oxysterol content , but no difference in ligand concentrations between tumour subtypes .
21-1	3445-3447	We	person	acc	_	_
21-2	3448-3456	recently	_	_	_	_
21-3	3457-3466	evaluated	_	_	_	_
21-4	3467-3470	LXR	abstract|abstract[183]	giv|new[183]	_	_
21-5	3471-3477	ligand	organization|abstract[183]	giv|new[183]	coref	21-26
21-6	3478-3494	bio-availability	abstract[183]	new[183]	_	_
21-7	3495-3497	in	_	_	_	_
21-8	3498-3499	a	person[185]	new[185]	_	_
21-9	3500-3505	small	person[185]	new[185]	_	_
21-10	3506-3509	BCa	abstract|person[185]	giv|new[185]	coref	22-18
21-11	3510-3516	cohort	person[185]	new[185]	_	_
21-12	3517-3520	and	_	_	_	_
21-13	3521-3526	found	_	_	_	_
21-14	3527-3532	large	abstract[186]	new[186]	_	_
21-15	3533-3538	inter	abstract[186]	new[186]	_	_
21-16	3539-3547	tumoural	abstract[186]	new[186]	_	_
21-17	3548-3561	heterogeneity	abstract[186]	new[186]	_	_
21-18	3562-3564	in	abstract[186]	new[186]	_	_
21-19	3565-3574	oxysterol	abstract[186]|abstract|abstract[188]	new[186]|new|new[188]	_	_
21-20	3575-3582	content	abstract[186]|abstract[188]	new[186]|new[188]	_	_
21-21	3583-3584	,	_	_	_	_
21-22	3585-3588	but	_	_	_	_
21-23	3589-3591	no	abstract[189]	giv[189]	_	_
21-24	3592-3602	difference	abstract[189]	giv[189]	_	_
21-25	3603-3605	in	abstract[189]	giv[189]	_	_
21-26	3606-3612	ligand	abstract[189]|organization|animal[191]	giv[189]|giv|giv[191]	_	_
21-27	3613-3627	concentrations	abstract[189]|animal[191]	giv[189]|giv[191]	_	_
21-28	3628-3635	between	abstract[189]|animal[191]	giv[189]|giv[191]	_	_
21-29	3636-3642	tumour	abstract[189]|animal[191]|abstract|abstract[193]	giv[189]|giv[191]|giv|giv[193]	coref|coref	22-18[205_193]|22-18[205_193]
21-30	3643-3651	subtypes	abstract[189]|animal[191]|abstract[193]	giv[189]|giv[191]|giv[193]	_	_
21-31	3652-3653	.	_	_	_	_

#Text=Systematic evaluation of scOHC bioavailability and activation potential , coupled with analysis of NR cofactor expression between BCa subtypes has not been performed previously .
22-1	3654-3664	Systematic	abstract[194]	new[194]	_	_
22-2	3665-3675	evaluation	abstract[194]	new[194]	_	_
22-3	3676-3678	of	abstract[194]	new[194]	_	_
22-4	3679-3684	scOHC	abstract[194]|abstract|abstract[196]|event[197]	new[194]|giv|new[196]|giv[197]	_	_
22-5	3685-3700	bioavailability	abstract[194]|abstract[196]|event[197]	new[194]|new[196]|giv[197]	_	_
22-6	3701-3704	and	abstract[194]|event[197]	new[194]|giv[197]	_	_
22-7	3705-3715	activation	abstract[194]|event[197]|abstract|abstract[199]	new[194]|giv[197]|giv|giv[199]	_	_
22-8	3716-3725	potential	abstract[194]|event[197]|abstract[199]	new[194]|giv[197]|giv[199]	_	_
22-9	3726-3727	,	_	_	_	_
22-10	3728-3735	coupled	_	_	_	_
22-11	3736-3740	with	_	_	_	_
22-12	3741-3749	analysis	abstract[200]	new[200]	_	_
22-13	3750-3752	of	abstract[200]	new[200]	_	_
22-14	3753-3755	NR	abstract[200]|person|abstract[203]	new[200]|new|giv[203]	_	_
22-15	3756-3764	cofactor	abstract[200]|person|abstract[203]	new[200]|new|giv[203]	_	_
22-16	3765-3775	expression	abstract[200]|abstract[203]	new[200]|giv[203]	_	_
22-17	3776-3783	between	abstract[200]|abstract[203]	new[200]|giv[203]	_	_
22-18	3784-3787	BCa	abstract[200]|abstract[203]|abstract|abstract[205]	new[200]|giv[203]|giv|giv[205]	coref|coref|coref|coref	23-9|23-24[213_205]|23-9|23-24[213_205]
22-19	3788-3796	subtypes	abstract[200]|abstract[203]|abstract[205]	new[200]|giv[203]|giv[205]	_	_
22-20	3797-3800	has	_	_	_	_
22-21	3801-3804	not	_	_	_	_
22-22	3805-3809	been	_	_	_	_
22-23	3810-3819	performed	_	_	_	_
22-24	3820-3830	previously	_	_	_	_
22-25	3831-3832	.	_	_	_	_

#Text=Given the prognostic and therapeutic value of stratifying BCa by hormone receptor status , further delineation of the pathways that are altered between these subtypes , such as scOHC-LXR signalling , may help advance understanding about the emerging roles of cholesterol metabolism in cancer and improve outcomes for patients .
23-1	3833-3838	Given	_	_	_	_
23-2	3839-3842	the	abstract[206]	new[206]	_	_
23-3	3843-3853	prognostic	abstract[206]	new[206]	_	_
23-4	3854-3857	and	abstract[206]	new[206]	_	_
23-5	3858-3869	therapeutic	abstract[206]	new[206]	_	_
23-6	3870-3875	value	abstract[206]	new[206]	_	_
23-7	3876-3878	of	_	_	_	_
23-8	3879-3890	stratifying	_	_	_	_
23-9	3891-3894	BCa	object	giv	_	_
23-10	3895-3897	by	_	_	_	_
23-11	3898-3905	hormone	substance|abstract[210]	new|giv[210]	_	_
23-12	3906-3914	receptor	substance|abstract[210]	giv|giv[210]	_	_
23-13	3915-3921	status	abstract[210]	giv[210]	_	_
23-14	3922-3923	,	_	_	_	_
23-15	3924-3931	further	abstract[211]	new[211]	_	_
23-16	3932-3943	delineation	abstract[211]	new[211]	_	_
23-17	3944-3946	of	abstract[211]	new[211]	_	_
23-18	3947-3950	the	abstract[211]|abstract[212]	new[211]|new[212]	_	_
23-19	3951-3959	pathways	abstract[211]|abstract[212]	new[211]|new[212]	_	_
23-20	3960-3964	that	_	_	_	_
23-21	3965-3968	are	_	_	_	_
23-22	3969-3976	altered	_	_	_	_
23-23	3977-3984	between	_	_	_	_
23-24	3985-3990	these	abstract[213]	giv[213]	_	_
23-25	3991-3999	subtypes	abstract[213]	giv[213]	_	_
23-26	4000-4001	,	abstract[213]	giv[213]	_	_
23-27	4002-4006	such	abstract[213]	giv[213]	_	_
23-28	4007-4009	as	abstract[213]	giv[213]	_	_
23-29	4010-4019	scOHC-LXR	abstract[213]|abstract|abstract[215]	giv[213]|giv|giv[215]	_	_
23-30	4020-4030	signalling	abstract[213]|abstract[215]	giv[213]|giv[215]	_	_
23-31	4031-4032	,	_	_	_	_
23-32	4033-4036	may	_	_	_	_
23-33	4037-4041	help	_	_	_	_
23-34	4042-4049	advance	_	_	_	_
23-35	4050-4063	understanding	abstract[216]	new[216]	_	_
23-36	4064-4069	about	abstract[216]	new[216]	_	_
23-37	4070-4073	the	abstract[216]|abstract[217]	new[216]|giv[217]	_	_
23-38	4074-4082	emerging	abstract[216]|abstract[217]	new[216]|giv[217]	_	_
23-39	4083-4088	roles	abstract[216]|abstract[217]	new[216]|giv[217]	_	_
23-40	4089-4091	of	abstract[216]|abstract[217]	new[216]|giv[217]	_	_
23-41	4092-4103	cholesterol	abstract[216]|abstract[217]|substance|abstract[219]	new[216]|giv[217]|giv|giv[219]	_	_
23-42	4104-4114	metabolism	abstract[216]|abstract[217]|abstract[219]	new[216]|giv[217]|giv[219]	_	_
23-43	4115-4117	in	abstract[216]|abstract[217]|abstract[219]	new[216]|giv[217]|giv[219]	_	_
23-44	4118-4124	cancer	abstract[216]|abstract[217]|abstract[219]|abstract	new[216]|giv[217]|giv[219]|giv	_	_
23-45	4125-4128	and	_	_	_	_
23-46	4129-4136	improve	_	_	_	_
23-47	4137-4145	outcomes	abstract	new	_	_
23-48	4146-4149	for	_	_	_	_
23-49	4150-4158	patients	person	giv	_	_
23-50	4159-4160	.	_	_	_	_
